Answers are grounded in this paper and cite their sources.
Lung adenocarcinoma (LUAD) remains clinically heterogeneous, and competing endogenous RNA (ceRNA) derived prognostic biomarkers require further characterization. This study integrated TCGA-LUAD RNA-seq, miRNA-seq, survival, mutation, and methylation data to generate a ceRNA network and develop a survival-associated signature. Differential expression analysis identified 4,686 mRNAs, 2,220 lncRNAs, and 264 miRNAs dysregulated between tumor and normal samples. The final ceRNA network contained 9 lncRNAs, 9 miRNAs, 117 mRNAs. Cox and LASSO analyses identified a two-RNA prognostic signature composed of ITGB1-DT and IGF2BP1. High-score patients showed shorter overall survival and the risk score remained independently associated with survival after adjustment for age, gender, and stage. External validation in CPTAC-LUAD supported the model mainly as a continuous prognostic score. The high-risk group showed immunosuppressive and hypoxia-related features, increased tumor mutation burden, higher TP53 mutation frequency, and reduced IGF2BP1 regulatory-region methylation associated with increased IGF2BP1 expression. These findings suggest that the ITGB1-DT and IGF2BP1 signature may serve as a prognostic biomarker for LUAD and provide insight into ceRNA-associated tumor features. Further experimental validation required.
No takes yet. Share an insight, caveat, or question.
Khan et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: